Here’s how the device companies compare in three areas:
1. Finances
DePuy Synthes: $2.1 billion revenue in Q1 2021
NuVasive: $271.2 million net sales in Q1 2021
Globus Medical: $227.3 million net sales in Q1 2021
2. No. of employees
DePuy Synthes: 12,000
NuVasive: 2,700
Globus Medical: 1,800
3. Executive leadership
DePuy Synthes: Aldo Denti, Company Group Chairman (2018 — present)
NuVasive: Chris Barry, CEO (2018 — present)
Globus Medical: David Demski, CEO (2017 — present)
4. Headquarters
DePuy Synthes: West Chester, Pa.
NuVasive: San Diego
Globus Medical: Audubon, Pa.
5. Year founded
DePuy Synthes: 1895
NuVasive: 1997
Globus Medical: 2003
6. Key spine, orthopedic products
DePuy Synthes: DePuy has an expansive portfolio including the Velys robotic-assisted solution, Attune total knee system and the Bi-Mentum Dual Mobility System.
NuVasive: NuVasive has a wide selection of spinal products including the eXtreme lateral interbody fusion procedure, Magec rods and Precice limb-lengthening system.
Globus Medical: Globus Medical’s portfolio comprises a variety of spinal screws, plates, biologics and its flagship ExcelsiusGPS robot.
7. Notable news this year
DePuy Synthes: Velys received FDA clearance for use with the Attune knee system.
NuVasive: NuVasive submitted its Pulse system and associated robotics application for FDA clearance, which are expected to launch this summer.
Globus Medical: Globus Medical launched Creo One, the market’s first robotic screw designed for spine surgery with ExcelsiusGPS.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
